For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 4,093 | 12,709* | 4,307 | 5,814 |
| General and administrative | 4,787 | 6,573* | 4,348 | 4,520 |
| Impairment of long-lived assets | - | 1,536* | - | - |
| Net gain on lease termination | 633 | - | - | - |
| Loss from operations | -8,247 | -20,818* | -8,655 | -10,334 |
| Other income (expense), net | 688 | 992* | 906 | 949 |
| Net loss | -7,559 | -19,827* | -7,749 | -9,385 |
| Unrealized gain (loss) on marketable securities | - | -2* | - | - |
| Comprehensive loss | -7,559 | -19,829 | -7,749 | -9,385 |
| Basic EPS | -2.36 | -6.253 | -2.44 | -2.96 |
| Diluted EPS | -2.36 | -6.253 | -2.44 | -2.96 |
| Basic Average Shares | 3,205,866 | 3,170,967 | 3,178,710 | 3,168,933 |
| Diluted Average Shares | 3,205,866 | 3,170,967 | 3,178,710 | 3,168,933 |
Passage BIO, Inc. (PASG)
Passage BIO, Inc. (PASG)